249 filings
Page 8 of 13
8-K
rwz649flxp1f
20 May 13
Submission of Matters to a Vote of Security Holders
12:00am
8-K
e572ty7rfll
2 May 13
Threshold Pharmaceuticals Reports First Quarter 2013 Financial and Operational Results
12:00am
8-K
76yib7s9t3vkm3s4
15 Mar 13
Departure of Directors or Certain Officers
12:00am
8-K
o8srt8z6koai
7 Mar 13
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2012 Financial and Operational Results
12:00am
8-K
vpc0gfvj71mxvm0ch
25 Jan 13
Other Events
12:00am
8-K
it84gk qzt96
15 Nov 12
Other Events
12:00am
8-K
rbtkb18 ck5uwaiv
2 Nov 12
Threshold Pharmaceuticals Reports Third Quarter 2012 Financial and Operational Results
12:00am
8-K
ea1w3 9ay3t0ikk0
16 Oct 12
Other Events
12:00am
8-K
dk60r
2 Oct 12
Other Events
12:00am
8-K
pqr2 s7496ck
17 Sep 12
Threshold Pharmaceuticals to Present Updated Data from Phase 2b
12:00am
8-K
4p2y1f
2 Aug 12
Threshold Pharmaceuticals Reports SECONd Quarter 2012 Financial AND OPERATIONAL Results
12:00am
8-K
1zknjqw qn8mx5ms
5 Jun 12
Threshold Pharmaceuticals Announces Highlights of TH-302 Presentations at 2012 American Society of Clinical Oncology Annual Meeting
12:00am
8-K
h9zfe0cpfaqe5mpd207h
18 May 12
Submission of Matters to a Vote of Security Holders
12:00am
8-K
dawwoqjt sf7ow
4 May 12
Threshold Pharmaceuticals Reports FIRST Quarter 2012 Financial AND OPERATIONAL Results
12:00am
8-K
ufb1w8uifjxq2dkw
12 Apr 12
Threshold Pharmaceuticals Earns $20 million Milestone Payment from Merck KGaA for Positive Results from Phase 2 Trial of TH-302 in Pancreatic Cancer
12:00am
8-K
j8ko51tm
12 Apr 12
Entry into a Material Definitive Agreement
12:00am
8-K
u805h82 inn4y0
30 Mar 12
Other Events
12:00am
8-K
qw2pc5dmxq c5
19 Mar 12
Threshold Pharmaceuticals' TH-302 Receives Orphan Drug Designation in the European Union for the Treatment of Soft Tissue Sarcoma
12:00am
8-K
qiwo3rjer94kl1vuy59
14 Mar 12
Other Events
12:00am
8-K
r6zjkp6f
8 Mar 12
Threshold Pharmaceuticals Reports Fourth Quarter and Year end 2011 Financial AND OPERATIONAL Results
12:00am